The Relative Strength (RS) Rating for TransMedics Group climbed into a higher percentile Thursday, as it got a lift from 69 to 78.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the top-performing stocks often have an 80 or higher RS Rating as they begin their largest runs. See if TransMedics Group can continue to show renewed price strength and clear that threshold.
TransMedics Group is not currently showing a potential entry point. See if the stock goes on to build a base that could launch a new move.
While the company's top line growth fell last quarter from 64% to 50%, EPS grew 58%, up from 0% in the previous report. Keep an eye out for the company's next round of numbers on or around May 6.
TransMedics Group earns the No. 12 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
